PD-L1 And PIK3CA Testing Market Report 2026

PD-L1 And PIK3CA Testing Market Overview

• PD-L1 And PIK3CA Testing market size has reached to $1.67 billion in 2025 • Expected to grow to $3.4 billion in 2030 at a compound annual growth rate (CAGR) of 15.2% • Growth Driver: Increasing Prevalence Of Cancer Is Fueling The Growth Of The Market Due To Rising Diagnosis Rates And Growing Demand For Targeted Treatments • Market Trend: Advancements In Precision Oncology Through Companion Diagnostic Integration • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under PD-L1 And PIK3CA Testing Market?

PD-L1 and PIK3CA testing are molecular diagnostic procedures used to identify specific biomarkers that guide targeted cancer treatment decisions. PD-L1 testing evaluates the expression of the programmed death-ligand 1 protein on tumor cells to determine potential response to immunotherapies. PIK3CA testing detects mutations in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene, helping to assess eligibility for therapies targeting the PI3K pathway. The main test types of PD-L1 and PIK3CA testing are immunohistochemistry, next-generation sequencing, polymerase chain reaction, and others. Immunohistochemistry is a laboratory technique that uses antibodies to detect specific proteins in tissue samples, allowing visualization of their location and abundance under a microscope. The different sample types are tissue samples and liquid biopsy samples. The multiple distribution channels are direct sales, distributors and resellers, and online sales platforms. The various applications involved are cancer diagnosis, drug development, research, and others, and they are used by several end users such as hospitals and clinics, laboratories, and pharmaceutical companies.

What Is The PD-L1 And PIK3CA Testing Market Growth Forecast?

The pd-l1 and pik3ca testing market size is expected to see rapid growth in the next few years. It will grow to $3.4 billion in 2030 at a compound annual growth rate (CAGR) of 15.2%. The growth in the forecast period can be attributed to integration of ai in biomarker detection, growth of liquid biopsy applications, expansion in precision oncology, partnerships between diagnostics and pharma companies, regulatory approvals for next-gen assays. Major trends in the forecast period include targeted cancer biomarker testing, ai-based mutation analysis, liquid biopsy adoption, integration with drug development, high-throughput genomic screening.

Global PD-L1 And PIK3CA Testing Market Segmentation

1) By Test Type: Immunohistochemistry, Next-Generation Sequencing, Polymerase Chain Reaction 2) By Sample Type: Tissue Samples, Liquid Biopsy Samples 3) By Applications: Cancer Diagnosis, Drug Development, Research, Other Applications 4) By End User: Hospitals And Clinics, Laboratories, Pharmaceutical Companies Subsegments: 1) By Immunohistochemistry: Tissue Staining, Protein Expression Analysis 2) By Next-Generation Sequencing: Whole Genome Sequencing, Targeted Gene Sequencing, Exome Sequencing, Ribonucleic Acid (RNA) Sequencing 3) By Polymerase Chain Reaction: Quantitative Polymerase Chain Reaction, Digital Polymerase Chain Reaction

What Is The Driver Of The PD-L1 And PIK3CA Testing Market?

The increasing prevalence of cancer is expected to propel the growth of the PD-L1 and PIK3CA testing market going forward. Cancer is a disease characterized by the uncontrolled growth and spread of abnormal cells in the body, that can invade surrounding tissues and potentially metastasize to other parts. The cancer prevalence is due to growing lifestyle-related risks and aging populations that are leading to higher diagnosis rates and greater demand for early detection and effective treatment solutions. PD-L1 and PIK3CA testing support the management of cancer by allowing for exact diagnosis and guiding targeted medicines, which help adapt treatment regimens to individual patients and improve clinical outcomes. For instance, in September 2024, according to the American Cancer Society, a US-based non-profit organization, global cancer cases in men is expected to rise by 84% by 2029, increasing from 10.3 million in 2022 to 19 million. Therefore, increasing prevalence of cancer is driving the growth of the PD-L1 and PIK3CA testing industry.

Key Players In The Global PD-L1 And PIK3CA Testing Market

Major companies operating in the pd-l1 and pik3ca testing market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Laboratory Corporation of America Holdings (Labcorp), Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Sonic Healthcare Limited, Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Myriad Genetics Inc., NeoGenomics Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Caris Life Sciences, Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., ACCB Biotech Private Limited, EntroGen Inc.

Global PD-L1 And PIK3CA Testing Market Trends and Insights

Major companies operating in the PD-L1 and PIK3CA testing market are focusing on technological advancements, such as companion diagnostic integration, to improve therapeutic targeting, enhance treatment efficacy, and support personalized medicine approaches in oncology. Companion diagnostic integration refers to enhanced, technology-driven testing systems designed in conjunction with targeted medicines to identify patient populations most likely to benefit from specific treatments based on biomarker profiles. For instance, in October 2024, F. Hoffmann-La Roche AG, a Switzerland-based biotechnology and pharmaceutical company, launched Itovebi (inavolisib) in combination with palbociclib and fulvestrant for adults with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer. The Food and Drug Administration (FDA), a US-based federal agency, approved the regimen, based on the pivotal Phase III INAVO120 study, that more than doubled progression-free survival compared with palbociclib and fulvestrant alone, represents Roche’s first targeted therapy for HR-positive disease, and integrates a companion diagnostic to identify eligible patients, marking a significant advancement in precision medicine for a patient population with limited first-line treatment options.

What Are Latest Mergers And Acquisitions In The PD-L1 And PIK3CA Testing Market?

In September 2025, Labcorp, a U.S.-based provider of comprehensive clinical laboratory services and drug development solutions, acquired select oncology and oncology-related clinical testing assets of BioReference Health for up to $225 million. With this acquisition, Labcorp aims to expand its oncology diagnostics portfolio and strengthen nationwide access to high-value cancer testing services by integrating BioReference’s specialized oncology capabilities and customer accounts. BioReference Health is a U.S.-based provider of oncology-focused laboratory testing services, offering advanced cancer diagnostics, clinical testing solutions, and regional clinical laboratory operations.

Regional Outlook

North America was the largest region in the PD-L1 and PIK3CA testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the PD-L1 And PIK3CA Testing Market?

The PD-L1 and PIK3CA testing market includes revenues earned by entities through the biomarker testing, molecular diagnostics, genetic mutation detection, generation sequencing services, companion diagnostic testing, pathology interpretation, and clinical trial testing support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.